Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Theranexus : THERANEXUS ANNOUNCES INCLUSION OF LAST SUBJECT IN ITS PHASE IB TRIAL OF THN201

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/17/2019 | 01:35am EST
  • This study compares the efficacy of THN201 with the standard-of-care drug in Alzheimer's disease associated neurocognitive disorders
  • Results are expected towards the end of 2019

Lyon, September 17, 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, has announced the inclusion of the last healthy subject in its Phase Ib trial comparing the pharmacological efficacy of its drug candidate THN201 with the standard-of-care treatment in Alzheimer's disease-related neurocognitive disorders.

A total of 152 healthy subjects were recruited at 10 sites in Europe. The trial was conducted as a double-blind, randomized, three arms, parallel study to evaluate the pro-cognitive activity, tolerance and pharmacokinetics of THN201 compared with the standard-of-care treatment alone or a placebo. THN201 has already demonstrated a preclinical pharmacological efficacy profile superior to the standard-of-care treatment in Alzheimer's disease and an excellent safety profile.

"We would like to thank Professor Régis Bordet, the Principal Investigator (University of Lille, Lille Teaching Hospital, Inserm), who conducted this trial with 9 other clinical trial sites in Europe and the volunteers who took part in the study. We look forward to obtaining the initial clinical efficacy data on THN201 because we are aware that treating neurocognitive disorders remains a major public health challenge today" concludes Franck Mouthon, CEO of Theranexus.

About the Phase Ib trial of THN 201 in Alzheimer's disease-related neurocognitive disorders

Alzheimer's disease (AD) is characterized by short-term memory loss, impairment of executive functions and temporal and spatial disorientation. Patients gradually lose their cognitive abilities and independence. Such neurocognitive disorders are particularly challenging, not only for patients but also for caregivers and families. Other diseases characterized by neurocognitive disorders (such as strokes or Parkinson's disease) currently represent a major unmet medical need and a significant economic burden. Health care costs associated with these neurocognitive disordersare estimated at over $640 billion worldwide and predominantly driven by specialized nursing home costs. These costs continue to increase dramatically. Indeed, over 45 million people currently have neurocognitive disorders worldwide and this figure is expected to exceed 75 million by 2030.

This multicenter study was conducted at 10 sites in Europe. It included 152 healthy volunteers. Patients were randomized to one of the two possible treatment arms (THN201 or donepezil alone) or to the placebo arm and treated for 15 days. On day 1, participants received a 50 mg oral dose of mefloquine in the THN201 arm or a corresponding placebo in either the placebo or the donepezil arms. THN201 repeated-dose treatments – mefloquine (10 mg) and donepezil (5 mg) or donepezil (5 mg) and placebo mefloquine, or placebo donepezil and placebo mefloquine – were administered orally once daily in the morning from D-1 to D-15. The tolerance and pharmacokinetics of THN201, compared with donepezil alone and the placebo, were evaluated repeatedly over the 15 days of treatment. On D-15, pro-cognitive activity was measured with a scopolamine challenge, a standard model for assessing the pro-cognitive activities of drug candidates in healthy volunteers.

As a reminder, the Phase Ib trial is an integral part of the CX-COG project. It is conducted in partnership with Lille Teaching Hospital and Synerlab Développement, funded by the French government's “Fonds Unique Interministériel” (FUI), FUI AAP22, and approved by the Lyonbiopôle and Atlanpôle Biothérapies competitive clusters.

ABOUT THERANEXUS
 
 
Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.
The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
More information at: www.theranexus.com 

 

 
Contacts

THERANEXUS
Thierry Lambert

Chief Financial Officer
investisseurs@theranexus.fr
 
 
 
ACTUS finance & communication
Caroline Lesage / Théo Martin

Investor Relations
+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
theranexus@actus.fr
 
FP2COM
Florence Portejoie

Media Relations
+ 33 (0)6 07 76 82 83
fportejoie@fp2com.fr
 


Regulated information:
Inside Information:
- other releases
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-60107-theranexus_pr_last_subject_thn201_vdef.pdf
Receive by email the next press releases of the company by registering on www.actusnews.com, it′s free


© 2019 ActusNews
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on THERANEXUS
12/12THERANEXUS : Theranexus and Beyond Batten Disease Foundation (BBDF) announce the..
AN
10/15THERANEXUS : Theranexus reports cash position as of september 30, 2019
AN
10/15THERANEXUS : 3rd quarter earnings
CO
09/26THERANEXUS : Theranexus announces its first half 2019 results
AN
09/24THERANEXUS : A new milestone reached for theranexus: inclusion of last patient i..
AN
09/17THERANEXUS : Theranexus announces inclusion of last subject in its phase ib tria..
AN
09/03THERANEXUS : Theranexus announces the publication of two scientific papers and a..
AN
07/11THERANEXUS : Theranexus raises approximately 2.2 million euros in a placement re..
AN
07/10THERANEXUS : Theranexus announces the launch of a capital increase by private pl..
AN
07/10THERANEXUS : Admission of new securities
CO
More news
Financials (EUR)
Sales 2019 0,10 M
EBIT 2019 -6,60 M
Net income 2019 -5,80 M
Finance 2019 5,10 M
Yield 2019 -
P/E ratio 2019 -2,30x
P/E ratio 2020 0,32x
EV / Sales2019 64,9x
EV / Sales2020 0,31x
Capitalization 11,6 M
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 8,90  €
Last Close Price 3,20  €
Spread / Highest target 238%
Spread / Average Target 178%
Spread / Lowest Target 119%
EPS Revisions
Managers
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial Officer
Mathieu Bernard Mari Charveriat Deputy CEO, Director & Chief Scientific Officer
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS-82.14%13
GILEAD SCIENCES5.15%83 209
VERTEX PHARMACEUTICALS32.15%56 311
REGENERON PHARMACEUTICALS0.78%41 151
WUXI APPTEC CO., LTD.76.88%22 016
GENMAB37.61%14 229